T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$1.3B |
| 2 |
American Airlines Group
AAL
|
+$853M |
| 3 |
Intuitive Surgical
ISRG
|
+$816M |
| 4 |
Morgan Stanley
MS
|
+$681M |
| 5 |
Wynn Resorts
WYNN
|
+$622M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Procter & Gamble
PG
|
+$1.4B |
| 2 |
eBay
EBAY
|
+$763M |
| 3 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$760M |
| 4 |
Broadcom
AVGO
|
+$757M |
| 5 |
US Bancorp
USB
|
+$686M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.64% |
| 2 | Consumer Discretionary | 13.46% |
| 3 | Financials | 12.79% |
| 4 | Industrials | 12.13% |
| 5 | Technology | 9.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AET
201
DELISTED
Aetna Inc
AET
| $567M | 0.12% |
6,995,773
-488,600
| -7% | -$37M |
|
|
WP
202
DELISTED
Worldpay, Inc.
WP
| $564M | 0.12% |
16,782,318
+833,328
| +5% | +$25.7M |
|
|
LM
203
DELISTED
Legg Mason, Inc.
LM
| $564M | 0.12% |
10,984,511
-1,582,961
| -13% | -$76.3M |
|
204
Bruker
BRKR
$8.68B
| $564M | 0.12% |
23,221,990
+1,804,340
| +8% | +$39.2M |
|
205
Murphy Oil
MUR
$5.12B
| $561M | 0.12% |
8,439,302
+371,997
| +5% | +$23.3M |
|
|
VIAB
206
DELISTED
Viacom Inc. Class B
VIAB
| $559M | 0.12% |
6,445,283
+3,411,127
| +112% | +$290M |
|
|
SE
207
DELISTED
Spectra Energy Corp Wi
SE
| $558M | 0.12% |
13,137,924
-305,122
| -2% | -$12.2M |
|
208
Progressive
PGR
$123B
| $557M | 0.12% |
21,957,316
-98,342
| -0.4% | -$2.44M |
|
209
Acuity Brands
AYI
$10.7B
| $557M | 0.12% |
4,026,151
-1,116,506
| -22% | -$142M |
|
210
Hilton Worldwide
HLT
$70.8B
| $546M | 0.12% |
7,815,513
+1,953,742
| +33% | +$130M |
|
211
BWX Technologies
BWXT
$15.6B
| $544M | 0.12% |
23,449,276
+202,057
| +0.9% | +$4.79M |
|
212
SM Energy
SM
$7.73B
| $539M | 0.12% |
6,413,546
-139,986
| -2% | -$10.7M |
|
213
ManpowerGroup
MAN
$2.62B
| $535M | 0.12% |
6,301,689
-771,800
| -11% | -$62.8M |
|
214
American Electric Power
AEP
$67.3B
| $528M | 0.11% |
9,459,945
-1,631,683
| -15% | -$86.1M |
|
215
Western Digital
WDC
$151B
| $523M | 0.11% |
7,501,324
+1,894,566
| +34% | +$127M |
|
|
MON
216
DELISTED
Monsanto Co
MON
| $519M | 0.11% |
4,156,722
-479,992
| -10% | -$56.2M |
|
|
CHK
217
DELISTED
Chesapeake Energy Corporation
CHK
| $517M | 0.11% |
88,430
+61,051
| +223% | +$333M |
|
218
AvalonBay Communities
AVB
$26B
| $516M | 0.11% |
3,630,908
+88,027
| +2% | +$12.2M |
|
219
Becton Dickinson
BDX
$49.4B
| $510M | 0.11% |
4,421,758
-593,483
| -12% | -$67.3M |
|
|
SIRO
220
DELISTED
SIRONA DENTAL SYSTEMS INC COM STK
SIRO
| $505M | 0.11% |
6,127,941
+11,553
| +0.2% | +$879K |
|
221
Flowserve
FLS
$10.3B
| $504M | 0.11% |
6,777,242
-610,105
| -8% | -$46.2M |
|
222
Chord Energy
CHRD
$7.62B
| $502M | 0.11% |
8,985,274
-418,787
| -4% | -$20.2M |
|
223
Sysco
SYY
$40.3B
| $499M | 0.11% |
13,315,922
+6,189,861
| +87% | +$227M |
|
224
Berkshire Hathaway Class B
BRK.B
$1.11T
| $498M | 0.11% |
3,935,615
+80,290
| +2% | +$10.2M |
|
|
WBA
225
DELISTED
Walgreens Boots Alliance
WBA
| $497M | 0.11% |
6,706,310
+4,478,732
| +201% | +$313M |
|
Similar funds
T. Rowe Price Associates's Q2 2014 Portfolio in Review
As of Q2 2014, T. Rowe Price Associates held 2,596 positions worth $463B, up 3.9% from $445B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
T. Rowe Price Associates's Q2 2014 filing shows 97 new, 1,091 increased, 793 reduced and 67 closed positions. Its largest new stake was Teva Pharmaceuticals: 4,638,481 shares worth $243M. The largest sale was Procter & Gamble, an estimated $1.4B.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2014 buy was Teva Pharmaceuticals: 4,638,481 shares worth $243M.
- T. Rowe Price Associates added most to Allergan Inc in Q2 2014, an estimated $1.3B increase.
- T. Rowe Price Associates's biggest Q2 2014 reduction was Procter & Gamble, cutting an estimated $1.4B.
- T. Rowe Price Associates fully exited Santander in Q2 2014, selling an estimated $134M.
- T. Rowe Price Associates's ten largest holdings make up 12% of its $463B portfolio in Q2 2014.
- T. Rowe Price Associates opened 97 new positions and closed 67 in Q2 2014.
- T. Rowe Price Associates's portfolio value rose 3.9% quarter-over-quarter to $463B.
Based on T. Rowe Price Associates's 13F filing for Q2 2014, filed 14 Aug 2014.